Compare UTL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | ARDX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 975.9M |
| IPO Year | 1995 | 2014 |
| Metric | UTL | ARDX |
|---|---|---|
| Price | $53.17 | $3.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $56.50 | $15.14 |
| AVG Volume (30 Days) | 85.8K | ★ 3.6M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $536,000,000.00 | $2,607,000.00 |
| Revenue This Year | $5.43 | $37.75 |
| Revenue Next Year | $4.22 | $34.24 |
| P/E Ratio | $24.87 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.17 | $3.56 |
| 52 Week High | $57.26 | $8.40 |
| Indicator | UTL | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 21.27 |
| Support Level | $52.10 | N/A |
| Resistance Level | $53.80 | $3.92 |
| Average True Range (ATR) | 0.99 | 0.12 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 20.25 | 2.80 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.